Effective combinatorial immunotherapy for castration-resistant prostate cancer
about
Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment.Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine.Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities.Modulation of cabozantinib efficacy by the prostate tumor microenvironment.The combination of checkpoint immunotherapy and targeted therapy in cancer.Phenotypic and clinical characterization of low density neutrophils in patients with advanced lung adenocarcinoma.Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.Revisiting ovarian cancer microenvironment: a friend or a foe?Myeloid-derived suppressor cells coming of age.Dendrimer-Based Signal Amplification of Click-Labelled DNA in Situ.Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma.The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo.Multifunctionalized biocatalytic P22 nanoreactor for combinatory treatment of ER+ breast cancer.Neutrophil elastase in the tumor microenvironment.STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer.Profiling Prostate Cancer Therapeutic Resistance.Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer.Small Molecules Drive Big Improvements in Immuno-Oncology Therapies.Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancer.PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer.Combined immunotherapy for advanced prostate cancer: Empowering the T cell army.Genetics and biology of prostate cancerRecent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defectsDiamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer TherapyTargeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers
P2860
Q33832752-5485F976-0C43-421A-9468-1D198A076196Q39429983-C97FE203-F704-484A-91D8-63D68CF15D0CQ39438805-E2B5CFC1-9976-47C8-AA3D-B4D6AE918CC0Q41369044-3BCCC096-6453-46FD-B4CB-4E8746D843FDQ46112903-7DAE3804-617F-4013-8F99-3C9936509691Q46493299-8374BA15-2753-4C66-BD8B-0C3A60B25F1CQ47100314-54412AEE-D67D-40F4-8A40-B81F3030AE10Q47157214-1806BA5A-A8CD-490E-A487-53796D7AF574Q47198804-A4C64882-F354-4C81-AE4E-93F63BF1FBCCQ47773956-D659716A-4A94-443E-9DBB-26A9D6192A56Q48215791-F5A984D9-3AED-4B05-8867-CDB6E4AD7FEAQ48236966-06E6AF78-6F91-4653-9ED1-C2B094B1337CQ48504970-534A61FD-2A53-4DE5-9E7A-C1E965D89C17Q49349544-47CD321C-8E4D-494D-B521-30A2FBDD6CC5Q49795880-0DDCC4A2-C477-4110-86CE-DA72D74328B7Q49861506-251C129B-0281-4521-88F0-208B70D63118Q52317592-B2B8BC82-A6BA-4C51-9239-2F1BDFD21A74Q52644478-C290088E-90D7-4D10-9E7C-D9AAD338B8F0Q52657103-00416085-2823-4B6B-A5D6-A72092C03BF3Q53047113-38788258-6872-4E2F-8A38-E9B178F1B9A6Q53741464-C557D7FD-5479-4B32-B0EB-ABBE62E308A3Q55249474-2238B12E-86E9-4CDC-9669-8CC7B9256296Q55343494-68FAA801-781B-4CE0-BBB3-7429C2CBA896Q55527258-E8DAAC40-9D72-44BE-AC9A-816C4F79FD10Q57106917-8834BB34-817C-4AF0-BCBE-17CB83E9F10DQ57108205-5B4E2F81-E68D-4D1D-B487-E2A424F472DDQ57817490-028BFA04-9850-4FAD-8D68-D04A7A09B875Q58694964-289441A3-0317-4747-9D91-F9D0E3AC58BF
P2860
Effective combinatorial immunotherapy for castration-resistant prostate cancer
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Effective combinatorial immunotherapy for castration-resistant prostate cancer
@en
type
label
Effective combinatorial immunotherapy for castration-resistant prostate cancer
@en
prefLabel
Effective combinatorial immunotherapy for castration-resistant prostate cancer
@en
P2093
P2860
P356
P1433
P1476
Effective combinatorial immunotherapy for castration-resistant prostate cancer
@en
P2093
Denise J Spring
James W Horner
John A Zebala
Padmanee Sharma
Patricia Troncoso
Pingna Deng
Qing Chang
Ronald A DePinho
Shan Jiang
P2860
P2888
P304
P356
10.1038/NATURE21676
P407
P50
P577
2017-03-20T00:00:00Z
P6179
1084128571